Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Avadel Pharmaceuticals PLC (AVDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AVDL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.57
1 Year Target Price $16.57
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.04% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 891.48M USD | Price to earnings Ratio - | 1Y Target Price 16.57 |
Price to earnings Ratio - | 1Y Target Price 16.57 | ||
Volume (30-day avg) 8 | Beta 1.63 | 52 Weeks Range 6.38 - 17.30 | Updated Date 06/30/2025 |
52 Weeks Range 6.38 - 17.30 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.58% | Operating Margin (TTM) -5.72% |
Management Effectiveness
Return on Assets (TTM) -7.21% | Return on Equity (TTM) -34.65% |
Valuation
Trailing PE - | Forward PE 22.17 | Enterprise Value 827895462 | Price to Sales(TTM) 4.58 |
Enterprise Value 827895462 | Price to Sales(TTM) 4.58 | ||
Enterprise Value to Revenue 4.26 | Enterprise Value to EBITDA -6.43 | Shares Outstanding 96900496 | Shares Floating 80290414 |
Shares Outstanding 96900496 | Shares Floating 80290414 | ||
Percent Insiders 4.83 | Percent Institutions 83.16 |
Analyst Ratings
Rating 3 | Target Price 16.57 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avadel Pharmaceuticals PLC
Company Overview
History and Background
Avadel Pharmaceuticals PLC, originally Flamel Technologies, was founded in 1990. It has evolved through strategic acquisitions and a focus on developing innovative pharmaceutical products, particularly for sleep disorders.
Core Business Areas
- Narcolepsy: Avadel focuses on developing and commercializing therapies for sleep disorders, primarily narcolepsy, with its lead product LUMRYZ.
Leadership and Structure
The leadership team includes Greg Divis, CEO, and other key executives in areas like finance, commercial operations, and research and development. The company operates with a functional structure, focusing on product development, sales, and marketing within the narcolepsy space.
Top Products and Market Share
Key Offerings
- LUMRYZ: LUMRYZ is a once-at-bedtime extended-release sodium oxybate for narcolepsy. It aims to provide a more convenient dosing regimen. Key competitors include Jazz Pharmaceuticals (Xyrem and Xywav). Market share is developing as the product gains traction.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on innovation and product development, especially in niche areas like sleep disorders.
Positioning
Avadel Pharmaceuticals is positioned as a specialty pharmaceutical company focused on developing differentiated products for sleep disorders, with LUMRYZ as a key growth driver. Their competitive advantage lies in the novel formulation and convenience of their product.
Total Addressable Market (TAM)
The narcolepsy market is estimated at $2-$3 billion. Avadel is positioned to capture a significant portion of this market with LUMRYZ, aiming for a substantial market share through its once-at-bedtime formulation.
Upturn SWOT Analysis
Strengths
- Novel product formulation (LUMRYZ)
- Focus on unmet medical needs in sleep disorders
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Dependence on a single product (LUMRYZ)
- Limited financial resources compared to larger pharmaceutical companies
- Potential for generic competition
- Challenges in market access and reimbursement
Opportunities
- Expansion into other sleep disorder indications
- Strategic partnerships and collaborations
- Further development of proprietary drug delivery technologies
- Increase in narcolepsy diagnosis rates
Threats
- Competition from established players (Jazz Pharmaceuticals)
- Regulatory hurdles and potential delays
- Pricing pressures from payers
- Adverse events or safety concerns
Competitors and Market Share
Key Competitors
- JAZZ
Competitive Landscape
Avadel faces stiff competition from Jazz Pharmaceuticals, which has established therapies for narcolepsy. Avadel's advantage lies in the novel formulation of LUMRYZ and its once-at-bedtime dosing, which could offer improved convenience for patients.
Major Acquisitions
Flamma S.p.A.
- Year: 2018
- Acquisition Price (USD millions): 19.3
- Strategic Rationale: Acquisition of Flamma S.p.A.'s drug delivery platform for development of oral sustained-release products.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the development and commercialization of LUMRYZ. Historical data requires access to past financial statements.
Future Projections: Future growth is expected to be driven by increasing sales of LUMRYZ and potential expansion into new indications. Analyst estimates vary.
Recent Initiatives: Recent initiatives include the launch and market penetration of LUMRYZ, as well as efforts to secure reimbursement and market access.
Summary
Avadel Pharmaceuticals is a specialty pharmaceutical company focused on sleep disorders. LUMRYZ is a key product driving growth, but the company faces competition from established players. While the novel formulation offers a competitive edge, financial strength and market access remain crucial. Avadel is working to expand and needs to increase their market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. All financial metrics are placeholders and require live financial statement data. Market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avadel Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-07 | CEO & Director Mr. Gregory J. Divis Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 188 | Website https://www.avadel.com |
Full time employees 188 | Website https://www.avadel.com | ||
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.